Cigna
About: Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.
Employees: 72,500
0
Funds holding %
of 6,812 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
28% more call options, than puts
Call options by funds: $1.2B | Put options by funds: $937M
23% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 111
17% more funds holding in top 10
Funds holding in top 10: 29 [Q2] → 34 (+5) [Q3]
2% more funds holding
Funds holding: 1,634 [Q2] → 1,660 (+26) [Q3]
3% more repeat investments, than reductions
Existing positions increased: 607 | Existing positions reduced: 592
0% more capital invested
Capital invested by funds: $83.7B [Q2] → $83.9B (+$238M) [Q3]
2.31% less ownership
Funds ownership: 89.14% [Q2] → 86.83% (-2.31%) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$377
37%
upside
Avg. target
$399
45%
upside
High target
$420
53%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Jessica Tassan 24% 1-year accuracy 5 / 21 met price target | 43%upside $394 | Overweight Reiterated | 5 Nov 2024 |
Barclays Andrew Mok 29% 1-year accuracy 18 / 62 met price target | 53%upside $420 | Overweight Maintained | 5 Nov 2024 |
Deutsche Bank George Hill 60% 1-year accuracy 6 / 10 met price target | 43%upside $394 | Buy Maintained | 4 Nov 2024 |
Stephens & Co. Scott Fidel 49% 1-year accuracy 21 / 43 met price target | 49%upside $410 | Overweight Reiterated | 1 Nov 2024 |
RBC Capital Ben Hendrix 27% 1-year accuracy 19 / 71 met price target | 37%upside $377 | Outperform Maintained | 1 Nov 2024 |
Financial journalist opinion
Based on 18 articles about CI published over the past 30 days
Negative
CNBC Television
1 week ago
Former Cigna VP: Health insurance industry has erect barriers making it more difficult to seek care
Wendell Potter, Center for Health and Democracy president and former Cigna vice president, joins 'Squawk Box' to discuss public anger at the health care industry, problems with health insurance, and more.
Positive
Zacks Investment Research
1 week ago
Cigna (CI) Soars 6.3%: Is Further Upside Left in the Stock?
Cigna (CI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Seeking Alpha
1 week ago
Humana, Cigna Plunge On Trump's Latest Promise: A Potential Buying Opportunity?
The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability.
Negative
Fast Company
1 week ago
UnitedHealth, CVS, and Cigna stock prices take another hit after Trump says he's going to ‘knock out' drug industry middlemen
Shares in major healthcare companies fell yesterday after president-elect Donald Trump made comments that he wanted to “knock out” prescription drug industry middlemen. The fall makes this yet another week since the killing of UnitedHealth CEO Brian Thompson that the business practices of companies that operate America's private healthcare system have come under increased scrutiny.
Negative
Reuters
2 weeks ago
Insurer stocks fall after Trump says 'we're going to knock out the middleman'
Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called them middlemen who drive up costs and said he plans to eliminate their role.
Positive
Seeking Alpha
2 weeks ago
Cigna: I'm Loading Up On This Dividend Growth Stock Now
Cigna's strong fundamentals, including consistent revenue and EPS growth, a solid balance sheet, and undervalued stock price, support a buy rating. The company's Q3 results showed a 29.9% revenue increase and a 10.9% rise in non-GAAP EPS, driven by customer growth and price hikes. Cigna's dividend yield and growth potential are robust, with a low payout ratio and projected double-digit annual EPS growth supporting future dividend increases.
Negative
Reuters
2 weeks ago
J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports
Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its pricier drugs, The Wall Street Journal reported on Friday.
Positive
Zacks Investment Research
2 weeks ago
Here's Why Cigna (CI) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Negative
CNBC Television
2 weeks ago
Senators Warren and Hawley introduce a bipartisan bill to break up pharmacy-benefit managers
CNBC's Bertha Coombs joins ‘The Exchange' to discuss a bipartisan bill introduced by Senators Elizabeth Warren and Josh Hawley aimed at breaking up pharmacy-benefit managers.
Negative
Market Watch
2 weeks ago
Cigna's stock leads selloff among drug middlemen on breakup fears — but this analyst says it's not a real risk
One influential healthcare analyst says the chances of such a bill passing are less than 5%.
Charts implemented using Lightweight Charts™